VCU Massey Cancer Center hosts annual research retreat
The annual Virginia Commonwealth University Massey Cancer Center Research Retreat showcases the most promising cancer research being conducted at Massey and throughout VCU and provides student researchers an opportunity to show off their contributions in the poster session, where they can receive up to $250 as Excellence in Cancer Research Awards winners. In addition to presentations from members of Massey’s research programs, this year’s keynote presentation featured Timothy Ley, M.D., who shared his work involving the acute myeloid leukemia (AML) genome.
Targeted viral therapy destroys breast cancer stem cells in preclinical experiments
A promising new treatment for breast cancer being developed at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) has been shown in cell culture and in animal models to selectively kill cancer stem cells at the original tumor site and in distant metastases with no toxic effects on healthy cells, including normal stem cells. Cancer stem cells are critical to a cancer’s ability to recur following conventional chemotherapies and radiation therapy because they can quickly multiply and establish new tumors that are often therapy resistant.
Top cancers among men
Top cancers among men: During National Men’s Health Awareness Month, learn about the top four cancers that affect men. These include lung cancer, prostate cancer, colon cancer and skin cancer.
HPV and cancer: what you may not know
According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 79 million Americans are currently infected with the human papillomavirus (HPV) and about 14 million people will become newly infected each year. The CDC goes on to say that “HPV is so common, nearly all sexually- active men and women will get at least one type of HPV at some point in their lives.” As a growing epidemic, HPV is not only the most common sexually transmitted infection, but also a rising cancer causer.
Biodegradable implant may lessen side effects of radiation to treat prostate cancer
Several years ago, Virginia Commonwealth University Massey Cancer Center became the first center in the United States to test an Israeli-invented device designed to increase the space between the prostate and the rectum in prostate cancer patients undergoing radiation therapy. Now, results from the international Phase I clinical trial show that the device has the potential to significantly reduce rectal injury, a side effect caused by unwanted radiation exposure that can leave men with compromised bowel function following treatment.